Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells

Virology

Volumn 446, Issue 1-2, 2013, Pages 268-275

  Sahu, Gautam K ^a   Sango, Kaori ^a   Selliah, Nithianandan ^a   Ma, Qiangzhong ^a   Skowron, Gail ^a   Junghans, Richard P ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

CD4 CD28 CD3 ; Chimeric antigen receptor; Cytotoxicity; Designer T cells; Gene modified T cells; HIV 1; Reactivation of latent HIV

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HLA DR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL LINE; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE; VIRUS CULTURE; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION;

CD4-CD28-CD3Ζ; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXICITY; DESIGNER T CELLS; GENE-MODIFIED T CELLS; HIV-1; REACTIVATION OF LATENT HIV;

ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD4; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84884521089     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.08.002     Document Type: Article

References (62)

1. Bagasra O., Lavi E., Bobroski L., Khalili K., Pestaner J.P., Tawadros R., Pomerantz R.J. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996, 10(6):573-585.
2. Beaudoin E.L., Bais A.J., Junghans R.P. Sorting vector producer cells for high transgene expression increases retroviral titer. J. Virol. Methods 2008, 148(1-2):253-259.
3. Beecham E.J., Ma Q., Ripley R., Junghans R.P. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death. J. Immunother. 2000, 23(6):631-642.
4. Boise L.H., Minn A.J., Noel P.J., June C.H., Accavitti M.A., Lindsten T., Thompson C.B. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995, 3(1):87-98.
5. Bosque A., Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009, 113(1):58-65.
6. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., Kuo Y.H., Brookmeyer R., Zeiger M.A., Barditch-Crovo P., Siliciano R.F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387(6629):183-188.
7. Chun T.W., Nickle D.C., Justement J.S., Meyers J.H., Roby G., Hallahan C.W., Kottilil S., Moir S., Mican J.M., Mullins J.I., Ward D.J., Kovacs J.A., Mannon P.J., Fauci A.S. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J. Infect. Dis. 2008, 197(5):714-720.
8. Clouse K.A., Powell D., Washington I., Poli G., Strebel K., Farrar W., Barstad P., Kovacs J., Fauci A.S., Folks T.M. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 1989, 142(2):431-438.
9. Davey R.T., Bhat N., Yoder C., Chun T.W., Metcalf J.A., Dewar R., Natarajan V., Lempicki R.A., Adelsberger J.W., Miller K.D., Kovacs J.A., Polis M.A., Walker R.E., Falloon J., Masur H., Gee D., Baseler M., Dimitrov D.S., Fauci A.S., Lane H.C. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 1999, 96(26):15109-15114.
10. Deeks S.G., Wagner B., Anton P.A., Mitsuyasu R.T., Scadden D.T., Huang C., Macken C., Richman D.D., Christopherson C., June C.H., Lazar R., Broad D.F., Jalali S., Hege K.M. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 2002, 5(6):788-797.
11. Emtage P.C., Clarke D., Gonzalo-Daganzo R., Junghans R.P. Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: Harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity. J. Immunother. 2003, 26(2):97-106.
12. Emtage P.C., Lo A.S., Gomes E.M., Liu D.L., Gonzalo-Daganzo R.M., Junghans R.P. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin. Cancer Res. 2008, 14(24):8112-8122.
13. Finney H.M., Akbar A.N., Lawson A.D. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 2004, 172(1):104-113.
14. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T.C., Chaisson R.E., Rosenberg E., Walker B., Gange S., Gallant J., Siliciano R.F. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5(5):512-517.
15. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278(5341):1295-1300.
16. Folks T.M., Clouse K.A., Justement J., Rabson A., Duh E., Kehrl J.H., Fauci A.S. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. USA 1989, 86(7):2365-2368.
17. Fu X.T., Karr R.W. HLA-DR alpha chain residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes. Hum. Immunol. 1994, 39(4):253-260.
18. Gao G.F., Rao Z., Bell J.I. Molecular coordination of alphabeta T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands. Trends Immunol. 2002, 23(8):408-413.
19. Garcia F., Plana M., Vidal C., Cruceta A., O'Brien W.A., Pantaleo G., Pumarola T., Gallart T., Miro J.M., Gatell J.M. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999, 13(11):F79-F86.
20. Green J.M., Noel P.J., Sperling A.I., Walunas T.L., Lenschow D.J., Stack R., Gray G.S., Bluestone J.A., Thompson C.B. T cell costimulation through the CD28 receptor. Proc. Assoc. Am. Physicians 1995, 107(1):41-46.
21. Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 1982, 155(6):1823-1841.
22. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.[see comment]. N. Engl. J. Med. 1997, 337(11):734-739.
23. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron J.J., Feinberg J.E., Balfour H.H., Deyton L.R., Chodakewitz J.A., Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.[see comment]. N. Engl. J. Med. 1997, 337(11):725-733.
24. Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res. 2010, 85(1):201-209.
25. Haynes N.M., Trapani J.A., Teng M.W., Jackson J.T., Cerruti L., Jane S.M., Kershaw M.H., Smyth M.J., Darcy P.K. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J. Immunol. 2002, 169(10):5780-5786.
26. Herrmann C.H., Carroll R.G., Wei P., Jones K.A., Rice A.P. Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. J. Virol. 1998, 72(12):9881-9888.
27. Hersperger A.R., Pereyra F., Nason M., Demers K., Sheth P., Shin L.Y., Kovacs C.M., Rodriguez B., Sieg S.F., Teixeira-Johnson L., Gudonis D., Goepfert P.A., Lederman M.M., Frank I., Makedonas G., Kaul R., Walker B.D., Betts M.R. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLOS Pathog. 2010, 6(5):e1000917.
28. Hill A.M., Cho M., Mrus J.M. The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients. AIDS Rev. 2011, 13(1):41-48.
29. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116(7):1035-1044.
30. Junghans R.P. A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays. Cancer Immunol. Immunother. 1990, 31(4):207-212.
31. Kataoka T., Shinohara N., Takayama H., Takaku K., Kondo S., Yonehara S., Nagai K. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 1996, 156(10):3678-3686.
32. Lambotte O., Taoufik Y., de Goer M.G., Wallon C., Goujard C., Delfraissy J.F. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2000, 23(2):114-119.
33. Lasky L.A., Nakamura G., Smith D.H., Fennie C., Shimasaki C., Patzer E., Berman P., Gregory T., Capon D.J. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987, 50(6):975-985.
34. Luzuriaga K., Bryson Y., Krogstad P., Robinson J., Stechenberg B., Lamson M., Cort S., Sullivan J.L. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N. Engl. J. Med. 1997, 336(19):1343-1349.
35. Lyons A.B., Parish C.R. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 1994, 171(1):131-137.
36. Ma Q., Gonzalo-Daganzo R.M., Junghans R.P. Genetically engineered T cells as adoptive immunotherapy of cancer. Cancer Chemother. Biol. Response Modif. 2002, 20:315-341.
37. Mata R.C., Viciana P., de Alarcon A., Lopez-Cortes L.F., Gomez-Vera J., Trastoy M., Cisneros J.M. Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences. AIDS Patient Care STDs 2005, 19(9):550-562.
38. Miller A.D., Garcia J.V., von Suhr N., Lynch C.M., Wilson C., Eiden M.V. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 1991, 65(5):2220-2224.
39. Mitsuyasu R.T., Anton P.A., Deeks S.G., Scadden D.T., Connick E., Downs M.T., Bakker A., Roberts M.R., June C.H., Jalali S., Lin A.A., Pennathur-Das R., Hege K.M. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000, 96(3):785-793.
40. Peterlin B.M., Trono D. Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat. Rev. Immunol. 2003, 3(2):97-107.
41. Poles M.A., Boscardin W.J., Elliott J., Taing P., Fuerst M.M., McGowan I., Brown S., Anton P.A. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J. Acquir. Immune Defic. Syndr. 2006, 43(1):65-68.
42. Roberts M.R., Qin L., Zhang D., Smith D.H., Tran A.C., Dull T.J., Groopman J.E., Capon D.J., Byrn R.A., Finer M.H. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994, 84(9):2878-2889.
43. Rosok B., Voltersvik P., Larsson B.M., Albert J., Brinchmann J.E., Asjo B. CD8+ T cells from HIV type 1-seronegative individuals suppress virus replication in acutely infected cells. AIDS Res. Hum. Retroviruses 1997, 13(1):79-85.
44. Sadelain M. T-cell engineering for cancer immunotherapy. Cancer J. 2009, 15(6):451-455.
45. Saez-Cirion A., Sinet M., Shin S.Y., Urrutia A., Versmisse P., Lacabaratz C., Boufassa F., Avettand-Fenoel V., Rouzioux C., Delfraissy J.F., Barre-Sinoussi F., Lambotte O., Venet A., Pancino G. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 2009, 182(12):7828-7837.
46. Sahu G.K., Lee K., Ji J., Braciale V., Baron S., Cloyd M.W. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology 2006, 355(2):127-137.
47. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., Kovacs C., Gange S.J., Siliciano R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 2003, 9(6):727-728.
48. Song S.K., Li H., Cloyd M.W. Rates of shutdown of HIV-1 into latency: roles of the LTR and tat/rev/vpu gene region. Virology 1996, 225(2):377-386.
49. Sonza S., Mutimer H.P., Oelrichs R., Jardine D., Harvey K., Dunne A., Purcell D.F., Birch C., Crowe S.M. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001, 15(1):17-22.
50. Thali M., Olshevsky U., Furman C., Gabuzda D., Li J., Sodroski J. Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J. Virol. 1991, 65(9):5007-5012.
51. Tsuchie H., Detorio M.A., Hossain M.M., Tesfamariam N., Trickett A., Lam-Po-Tang P.R., Yamada O., Ichimura H., Dwyer J.M., Kurimura T. Suppression of HIV replication in vitro by CD8+ T-cells from HIV-infected and HIV-seronegative individuals. Int. J. STD AIDS 1997, 8(5):307-310.
52. Tyagi M., Pearson R.J., Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 2010, 84(13):6425-6437.
53. Walker R.E., Bechtel C.M., Natarajan V., Baseler M., Hege K.M., Metcalf J.A., Stevens R., Hazen A., Blaese R.M., Chen C.C., Leitman S.F., Palensky J., Wittes J., Davey R.T., Falloon J., Polis M.A., Kovacs J.A., Broad D.F., Levine B.L., Roberts M.R., Masur H., Lane H.C. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000, 96(2):467-474.
54. Wang J.H., Meijers R., Xiong Y., Liu J.H., Sakihama T., Zhang R., Joachimiak A., Reinherz E.L. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc. Natl. Acad. Sci. USA 2001, 98(19):10799-10804.
55. Wang R.F., Wang X., Atwood A.C., Topalian S.L., Rosenberg S.A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999, 284(5418):1351-1354.
56. Weber S., Karjalainen K. Mouse CD4 binds MHC class II with extremely low affinity. Int. Immunol. 1993, 5(6):695-698.
57. Wong J.K., Hezareh M., Gunthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278(5341):1291-1295.
58. Yang O.O., Tran A.C., Kalams S.A., Johnson R.P., Roberts M.R., Walker B.D. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc. Natl. Acad. Sci. USA 1997, 94(21):11478-11483.
59. Yang W., Beaudoin E.L., Lu L., Du Pasquier R.A., Kuroda M.J., Willemsen R.A., Koralnik I.J., Junghans R.P. Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML). Int. Immunol. 2007, 19(9):1083-1093.
60. Yewdell J.W., Hill A.B. Viral interference with antigen presentation. Nat. Immunol. 2002, 3(11):1019-1025.
61. Zalar A., Figueroa M.I., Ruibal-Ares B., Bare P., Cahn P., de Bracco M.M., Belmonte L. Macrophage HIV-1 infection in duodenal tissue of patients on long term HAART. Antiviral Res. 2010, 87(2):269-271.
62. Zhu T., Muthui D., Holte S., Nickle D., Feng F., Brodie S., Hwangbo Y., Mullins J.I., Corey L. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J. Virol. 2002, 76(2):707-716.